Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation
Introduction
Post-transplant lymphoproliferative disorders (PTLD) are a well-recognised and potentially life-threatening complication after solid organ transplantation. There is no universally accepted definition of the term PTLD but it is most commonly used to describe a wide spectrum of lymphoproliferative disorders after solid organ and haematopoietic cell transplantation that range from infectious mononucleosis and lymphoid hyperplasia to highly invasive malignant lymphoma. PTLD after solid organ transplantation nearly always originates from recipient lymphoid cells whereas after bone-marrow or stem cell transplantation, PTLD is usually of donor origin. Most cases of PTLD after both solid organ and haematopoietic cell transplantation are associated with Epstein Barr virus (EBV) that leads to uncontrolled B cell proliferation and tumour formation. Although there are many similarities between PTLD after solid organ transplantation and after haematopoietic cell transplantation, only the former is considered further in this review.
PTLD is a relatively common malignancy after transplantation and is seen in up to 10% of all solid organ transplant recipients [1]. It is the most common form of post-transplant malignancy in children and in adults it is the second most common malignancy after skin cancer [2], [3]. In both children and adults it is the most common cause of cancer-related mortality after solid organ transplantation and the reported overall mortality for PTLD often exceeds 50% [4], [5], [6]. There have been several informative reviews of PTLD published elsewhere over the last 2 years (see [7], [8], [9], [10]). This review provides an update on the pathogenesis and clinical features of PTLD after solid organ transplantation and discusses recent progress in management.
Section snippets
Pathological classification of PTLD
PTLD encompasses a wide spectrum of lymphoproliferative disorders with differing pathogenesis, histological appearance and clinical behaviour. In Europe and the U.S., about 85% of PTLD are of B cell lineage [4], [11] and most of these (over 80%) are associated with EBV infection [12]. Around 10–15% of PTLD are of T cell lineage, around 30% of which are associated with EBV [12]. Other haematopoietic cell lineages, such as natural killer cells, may very occasionally give rise to PTLD [13], [14].
The role of EBV in the development of PTLD
EBV is closely involved in the pathogenesis of PTLD and the majority of cases of PTLD arise in response to primary infection with EBV or to re-activation of previously acquired EBV [6], [18], [19]. EBV belongs to the gamma herpes virus family and over 95% of the world's population acquire EBV in childhood or early adolescence [20]. Infection in normal individuals is often asymptomatic, though it may result in a self-limiting, benign lymphoproliferative syndrome termed infectious mononucleosis.
Incidence
The incidence of PTLD after solid organ transplantation is markedly different in children and adults and also varies according to the type of organ transplant. In adult recipients, PTLD has been reported to occur in 1–2.3% of kidney transplants, 1–2.8% of liver transplants, 1–6.3% of heart transplants, 2.4–5.8% of heart-lung transplants, 4.2–10% of lung transplants and up to 20% of small bowel transplants [4], [10], [11], [31], [32], [33], [34], [35]. The incidence of PTLD is significantly
Immunosuppressive agents and PTLD
PTLD arises, in large part, as a consequence of the potent immunosuppressive agents necessary to prevent allograft rejection. The number of different immunosuppressive agents available for use after organ transplantation has increased markedly over the last two decades and most recipients receive multiple agents. The effect of different immunosuppressive protocols on the development of PTLD has been examined in two large cohort studies. Libertiny et al. [35] reported a single centre analysis of
Clinical features
The clinical presentation of PTLD is highly variable. Most patients present with fever (seen in 50%), lymphadenopathy (seen in 30%) or non-specific symptoms such as tonsillitis (particularly children) and weight loss [17]. Around 15% of patients present as an emergency with intestinal perforation [17]. A small group of patients present with fulminant PTLD characterised by disseminated systemic disease that clinically resembles septic shock [45]. PTLD may involve the lymph nodes or extranodal
Diagnosis of PTLD
The diagnosis of PTLD should be based on histological examination of biopsy tissue. Excision biopsy is preferable and needle biopsy should only be performed where excision of affected tissue in not practicable. Fine needle aspiration and cytology is not adequate for classifying PTLD and has little role. Tissue should be subjected to standard histology, examined for the presence of EBV by immunostaining or in-situ hybridisation, cellular infiltrates characterised by relevant phenotypic markers
Treatment
The management of PTLD poses a major therapeutic challenge and although there is reasonable agreement about the overall principles of treatment, there is still considerable controversy about the optimal treatment of individual patients. It is important that treatment is directed by an oncologist/haemaologist with an interest in lymphoma working closely with the appropriate transplant clinicians. Treatment can be considered under a number of different headings (Table 2).
Prophylaxis of EBV and PTLD
Most PTLD arises as a consequence of EBV infection and prophylactic measures should include avoiding over-immunosuppression of the recipient, in particular avoiding anti-lymphocyte preparations which are a significant risk factor. Other ways of preventing or controlling EBV infection, such as antiviral agents, EBV vaccination and in-vitro generated EBV-specific CTL lines are currently under development. In EBV seronegative recipients avoiding transplantation with an organ from an EBV positive
Conclusion
PTLD remains a serious complication after solid organ transplantation and most cases are EBV-related B cell tumours resulting from impaired immunity due to immunosuppressive therapy. Reduction in immunosuppressive treatment is a key component of therapy and may lead to remission in early disease. Chemotherapy is standard therapy when reduced immunosuppression fails to control early disease and as initial therapy for most cases of late disease. Manipulation of the cytokine environment, the use
Anna Taylor is a research fellow in the Department of Surgery, University of Cambridge. After qualifying in medicine at the University of Sheffield, she undertook surgical training at Cambridge and is currently working towards a Ph.D. in transplantation immunology from the University of Cambridge.
References (91)
- et al.
Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease
Blood Rev
(2004) - et al.
Tumors and transplantation: the 2003 third annual ASTS state-of-the-art winter symposium
Am J Transplant
(2003) - et al.
Lymphomas after solid organ transplantation: a collaborative transplant study report
Am J Transplant
(2004) - et al.
Lymphoproliferative disorders after liver transplantation
J Hepatol
(2004) - et al.
Clinical characteristics of post-transplant lymphoproliferative disorders
Am J Med
(1994) - et al.
A gene polymorphism associated with posttransplant lymphoproliferative disorder
Transplant Proc
(2001) - et al.
Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases
J Heart Lung Transplant
(2001) - et al.
Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients
J Heart Lung Transplant
(2002) - et al.
Current induction immunosuppression and post-heart transplant lymphoproliferative disorders
Transplant Proc
(2003) - et al.
Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University
J Heart Lung Transplant
(2003)
Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients
J Pediatr
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
Lancet
The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies
Hum Pathol
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients
Am J Transplant
Therapy for transplant-related lymphoproliferative diseases
Hematol Oncol Clin North Am
BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome
Blood
The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients
J Hepatol
Monoclonal antibody therapy for lymphoma
Blood Rev
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
Blood
Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation
J Heart Lung Transplant
Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
Lancet
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases
J Hepatol
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial
Blood
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
Lancet
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
Blood
Prompt versus preemptive intervention for EBV lymphoproliferative disease
Blood
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
Lancet
Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication
Blood
Incidence and consequences of post-transplantation lymphoproliferative disorders
J Nephrol
Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center
J Clin Oncol
Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression
Transplantation
The post-transplant lymphoproliferative disorder-a literature review
Pediatr Nephrol
New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients
Clin Infect Dis
Post-transplant lymphoproliferative disorders
Annu Rev Med
Lymphoproliferative disorders in renal transplant patients in Japan
Int J Cancer
Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multi-centre experience
Pediatr Transplant
Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis
Br J Haematol
Posttransplant lymphoproliferative disorders: summary of society for hematopathology workshop
Semin Diagn Pathol
Lymphoproliferative disorders after organ transplantation in children
Transplantation
An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation
Transplantation
Epstein-Barr virus and haematological malignancies
Interleukin-6 production in posttransplant lymphoproliferative disease
J Clin Invest
Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders
Transplantation
Cited by (0)
Anna Taylor is a research fellow in the Department of Surgery, University of Cambridge. After qualifying in medicine at the University of Sheffield, she undertook surgical training at Cambridge and is currently working towards a Ph.D. in transplantation immunology from the University of Cambridge.
Robert Marcus is a consultant haematologist at Addenbrookes NHS Trust. He qualified in medicine at UCL and pursued postgraduate training in haematology in London. He was appointed as a consultant haematologist in 1987 and directs the Lymphoma service at Addenbrookes Hospital and in the West Anglia Cancer Network. He has a particular interest in the use of antibodies in the therapy of lymphoma.
J. Andrew Bradley is Professor of Surgery at the University of Cambridge, UK. He is an honorary consultant surgeon and clinical director of transplantation at Addenbrooke's hospital, Cambridge. After qualifying in medicine at the University of Leeds, he undertook surgical training in Leeds and Glasgow. He obtained a Ph.D. from the University of Glasgow and was based at the Western Infirmary, Glasgow until moving to Cambridge in 1997.